Intercell acquires Antibody Technology Platform from Cytos

Intercell AG, a public biotechnology company specialized in the development of novel vaccines for the prevention and treatment of infectious diseases, has announced that it has agreed to acquire the platform technology for monoclonal antibody discovery from SIX-listed Cytos Biotechnology Ltd. The technology is based on expression of cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases. Under the agreed terms, Intercell will own certain unpartnered monoclonal antibody assets and the key scientists who have developed the technology will be employed by Intercell.

Lenz & Staehelin advises Intercell in this transaction. The team includes Beat Kühni (M&A, Corporate), Thierry Calame (IP), Maja Baumann (M&A, Corporate) and Ruedi Ackermann.